Relative contributions of biomarkers in alzheimer's disease

Annals of Epidemiology

Volumn 22, Issue 12, 2012, Pages 868-875

  Haight, Thaddeus J ^a   Jagust, William J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biological markers; Causality; Dementia; Longitudinal studies

Indexed keywords

AMYLOID BETA PROTEIN; FLUORODEOXYGLUCOSE F 18; GLUCOSE;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; BRAIN SCINTISCANNING; BRAIN SIZE; CEREBROSPINAL FLUID ANALYSIS; COGNITION; DISEASE COURSE; FEMALE; GLUCOSE METABOLISM; HIPPOCAMPUS; HIPPOCAMPUS VOLUME; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RATING SCALE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BRAIN; CANADA; DISEASE PROGRESSION; FEMALE; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; RISK FACTORS; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 84870241130     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2012.09.004     Document Type: Article

References (42)

1. 2012 Alzheimer's disease facts and figures. Alzheimers Dement 2012, 131-168. Alzheimer's Association.
2. Neurological Disorders-Public Health Challenges 2006, World Health Organization, World Health Organization, Geneva.
3. Kuller L.H., Shemanski L., Manolio T., Haan M., Fried L., Bryan N., et al. Relationship between ApoE, MRI findings, and cognitive function in the Cardiovascular Health Study. Stroke 1998, 29:388-398.
4. Vermeer S.E., Prins N.D., den Heijer T., Hofman A., Koudstaal P.J., Breteler M.M.B. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003, 348(13):1215-1222.
5. Hofman A., Breteler M.M., van Duijn C.M., Krestin G.P., Pols H.A., Stricker B.H., et al. The Rotterdam Study: objectives and design update. Eur J Epidemiol 2007, 22(11):819-829.
6. Barnes D.E., Haight T.J., Mehta K.M., Carlson M.C., Kuller L.H., Tager I.B. Secondhand smoke, vascular disease, and dementia incidence: findings from the Cardiovascular Health Cognition Study. Am J Epidemiol 2010, 171(3):292-302.
7. Inaba M., White L., Bell C., Chen R., Petrovitch H., Launer L., et al. White matter lesions on brain magnetic resonance imaging scan and 5-year cognitive decline: the Honolulu-Asia aging study. J Am Geriatr Soc 2011, 59(8):1484-1489.
8. Craig-Schapiro R., Fagan A.M., Holtzman D.M. Biomarkers of Alzheimer's disease. Neurobiol Dis 2009, 35(2):128-140.
9. Weiner M.W., Aisen P.S., Jack C.R., Jagust W.J., Trojanowski J.Q., Shaw L., et al. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 2010, 6(3). 202-11.e7.
10. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9(1):119-128.
11. Clark C.M., Davatzikos C., Borthakur A., Newberg A., Leight S., Lee V.M., et al. Biomarkers for early detection of Alzheimer pathology. Neurosignals 2008, 16(1):11-18.
12. Jagust W.J., Landau S.M., Shaw L.M., Trojanowski J.Q., Koeppe R.A., Reiman E.M., et al. Relationships between biomarkers in aging and dementia. Neurology 2009, 73(15):1193-1199.
13. Landau S.M., Harvey D., Madison C.M., Reiman E.M., Foster N.L., Aisen P.S., et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010, 75(3):230-238.
14. Jack C.R., Wiste H.J., Vemuri P., Weigand S.D., Senjem M.L., Zeng G., et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010, 133(11):3336-3348.
15. Robins J.M., Hernan M.A., Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000, 11:550-560.
16. Cook N.R., Cole S.R., Hennekens C.H. Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physician's Health Study. Am J Epidemiol 2002, 155:1045-1053.
17. Bodnar L.M., Davidian M., Siega-Riz A.M., Tsiatis A.A. Marginal structural models for analyzing causal effects of time-dependent treatments: an application in perinatal epidemiology. Am J Epidemiol 2004, 159(10):926-934.
18. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999, 56(3):303-308.
19. Petersen R.C., Aisen P.S., Beckett L.A., Donohue M.C., Gamst A.C., Harvey D.J., et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010, 74(3):201-209.
20. ADNI Information Site. Alzheimer's Disease Neuroimaging Initiative, 2012 [accessed 12.03.12]. http://www.adni-info.org/.
21. Mohs R.C., Knopman D., Petersen R.C., Ferris S.H., Ernesto C., Grundman M., et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997, 11(Suppl 2):S13-S21.
22. Jack C.R., Bernstein M.A., Borowski B.J., Gunter J.L., Fox N.C., Thompson P.M., et al. Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. Alzheimers Dement 2010, 6(3):212-220.
23. Freesurfer Software Site. Cortical reconstruction and volumetric segmentation, 2012 [accessed 08.20.12]. http://surfer.nmr.mgh.harvard.edu/.
24. Alzheimer's Disease Neuroimaging Initiative. PET Protocols, 2012 [accessed 08.20.12]. http://adni.loni.ucla.edu/research/protocols/pet-protocols/#acquisition.
25. Landau S.M., Harvey D., Madison C.M., Koeppe R.A., Reiman E.M., Foster N.L., et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 2009, 32(7):1207-1218.
26. Jagust W.J., Bandy D., Chen K., Foster N.L., Landau S.M., Mathis C.A., et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 2010, 6(3):221-229.
27. Trojanowski J.Q., Vandeerstichele H., Korecka M., Clark C.M., Aisen P.S., Petersen R.C., et al. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement 2010, 6(3):230-238.
28. Fagan A.M., Mintun M.A., Shah A.R., Aldea P., Roe C.M., Mach R.H., et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 2009, 1(8-9):371-380.
29. Robins J.M. Association, causation, and marginal structural models. Synthese 1999, 121:151-179.
30. Greenland S., Robins J., Pearl J. Confounding and collapsibility in causal inference. Stat Sci 1999, 14(1):29-46.
31. van der Laan M.J., Robins J. Unified Methods for Censored Longitudinal Data and Causality 2002, Springer, New York.
32. Hernan M., Brumback B., Robins J. Marginal structural models to estimate causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000, 11(5):561-570.
33. van der Laan M, Dudoit S, van der Vaart AW. The cross-validated adaptive epsilon-net estimator, p. 142, 2004 [accessed 29.9.12]. http://biostats.bepress.com/cgi/viewcontent.cgi%3farticle%3d1141%26context%3ducbbiostat.
34. Efron B., Tibshirani R.J. An Introduction to the Bootstrap 1993, Chapman and Hall, New York. http://works.bepress.com/mark_van_der_laan/103.
35. Jack C.R., Dickson D.W., Parisi J.E., Xu Y.C., Cha R.H., O'Brien P.C., et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002, 58(5):750-757.
36. Korf E.S., Wahlund L.O., Visser P.J., Scheltens P. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology 2004, 63(1):94-100.
37. Jack C.R., Lowe V.J., Weigand S.D., Wiste H.J., Senjem M.L., Knopman D.S., et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132(Pt 5):1355-1365.
38. Jack C.R., Shiung M.M., Weigand S.D., O'Brien P.C., Gunter J.L., Boeve B.F., et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005, 65(8):1227-1231.
39. Sinisi S, van der Laan M. Loss-Based Cross-Validated Deletion/Substitution/Addition Algorithms in Estimation. Berkeley Electronic Press/U.C. Berkeley Biostatistics Division Working Paper, p. 143, 2004 [accessed 29.9.12]. http://biostats.bepress.com/cgi/viewcontent.cgi%3farticle%3d1142%26context%3ducbbiostat.
40. Haight T.J., Wang Y., van der Laan M.J., Tager I. Cross-validation deletion-substitution-addition model selection algorithm: Application to marginal structural models. Computational Stat Data Analysis 2010, 54(12):3080-3094.
41. Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr, 2004;16(2):129-40. http://works.bepress.com/mark_van_der_laan/172.
42. Panza F., D'Introno A., Colacicco A.M., Capurso C., Del Parigi A., Caselli R.J., et al. Current epidemiology of mild cognitive impairment and other predementia syndromes. Am J Geriatr Psychiatry 2005, 13(8):633-644.